Oculis’ Post

The webinar Syenza hosted last week was on medicine price transparency and pathways to fair pricing. The webinar started with an explanation of transparent medicine pricing and a quantitative definition for fair pricing. We had people joining from all around the globe, appreciated, guys! We also reviewed managed entry agreements and direct price negotiations, specifically the US Inflation Reduction Act. I gave an update on a recent paper I published in the Journal of Medical Economics with inspiration from discussions at the WHO Fair Pricing Forum. The session wasn't all about listening - there were polls to see what each participant thought about the most important strategies and challenges, like whether transparent policies would result in affordable health care. Check out the video below for more details. #SyenzaEvents #pharmaceuticals #medtech #healthtech #oncology #innovation

Despite ambitious goals, Pear Therapeutics faced go-to-market challenges and revenue difficulties. Now, nearly one year following Pear’s bankruptcy, the company’s assets have been acquired by four prominent players in the industry. What does this mean for DTx? Let's discuss! Join the waitlist for an insightful discussion on: 🔍 Broader implications for the digital health industry. 🚀 Confidence in digital therapeutics technology and future market shaping. 💡 Revenue generation strategies with innovative product lines. Meeting Full. JOIN THE WAITLIST NOW ➡️ https://lnkd.in/g-ujacYw #digitalhealth #digitaltherapeutics #healthtech

If you have clinician colleagues who need CME or you are curious about DTx, check out our introductory course!

Will there be a new wave M&A in Europe in digital therapeutics (DTx)? Maybe, but first the market access will have to become clearer and faster. No one can really argue that digital therapeutics will not be a significant part of healthcare of the future. The global DTx market size in 2023 was reported to be around USD 6.2 billion (Grand View Research, Inc) with compound annual growth rate (CAGR) of 27.2% from 2024 to 2030. But the market access of DTx in Europe remains to catch up to enable this M&A activity - from legislation perspective (yet again) and practical aspects. Klaudia P. and I, wrote a brief article on the current status of market access of DTx accross Europe. We are yet to see, what is the pathway from Medical Device Regulation to quicker and more effective market access and reimbursement. Link to the article in comments below. #mentsattorneys #MedTech #healthcaretransactions Ments

Far too frequently do we see early-stage companies select a preclinical pathway for the wrong drug candidate targeting the wrong indication, inevitably leading to increased costs and delayed program advances, much of which can be avoided with input from an experienced Chief Medical Officer (CMO) executive. To that end I wanted to reach out to highlight our creation of the BJC Capital Advisors’ CMO executive network and underscore the benefit, especially for companies in preclinical development, of accessing an experienced CMO talent to align preclinical programs with your anticipated clinical development strategy.  We encourage you to learn more here - bit.ly/3S5QXh9

Are you facing challenges with your clinical trial timelines or searching for a reliable, experienced CRO partner? At Altasciences, we understand the importance of streamlining your drug development process while ensuring the highest quality results. We provide a comprehensive, North American solution that can significantly enhance your clinical trials. Have a look at these resources: 1- Podcast—Benefits of Conducting a Clinical Trial in Canada: https://lnkd.in/gjgVUmMq 2- Video—Follow Your Sample From the Clinic to the Lab: https://lnkd.in/gTXfp_Mp 3- The Altascientist—Phase I Ethnobridging Clinical Trials: https://lnkd.in/gTAD8y9x 4- The Altascientist—Studying the Effects of Drugs on Driving: https://lnkd.in/gC6ngXHp 5- The Altascientist—Human Abuse Potential Studies: https://lnkd.in/gJnzJZpC 6- Video—Specialized Ophthalmology Expertise: https://lnkd.in/giPybUAb #ClinicalTrials #DrugDevelopment #ResearchAndDevelopment

At GE HealthCare, we believe in the power of Theranostics to pioneer a more personalized form of medicine, where innovative tools and technology allow clinicians to treat each patient as an individual, recognizing that the same treatment plan and dose doesn’t work for everyone. This supports the goal of creating more effective medical care. Today we announced our latest Theranostics FDA 510(k) clearance to perform absorbed dose calculations using a Monte Carlo method in radiopharmaceutical therapy with MIM SurePlan MRT. The Monte Carlo method is considered a “gold standard” for radiopharmaceutical therapy dosimetry and has been shown to achieve high calculation accuracy in tissues and tumors. In combination with MIM SurePlan MRT, we are excited to offer healthcare organizations this new tool for radiopharmaceutical therapy. Monte Carlo dosimetry via the Dose Planning Method (DPM) will be available for use with MIM SurePlan MRT, MIM Software’s comprehensive solution for automating and standardizing dosimetry in Theranostics. Learn more about this new precision care and Theranostics tool: https://lnkd.in/gMJJKw3Y #GEHealthCare #FutureofHealthcare #MedTech #PrecisionCare #Innovation #Theranostics

"If we listen to our sites and leverage existing site platforms, there may not be a need to invest in new technology or vendor services to implement DCTs or hybrid studies... The site-centric approach also decreases complexity and principal investigator (PI) oversight burden." — Noelle Gaskill, Head of Clinical Research Collaborations at Mirati Therapeutics. Read more insights in the ACRP blog > https://bit.ly/3T5ahLX Learn more during Noelle's #ACRP2024 session > https://bit.ly/3T5ahLX #GoForIt #GoForEducation #ClinicalResearch #ClinicalTrials #DecentralizedClinicalTrials #DCTs

Download the newest Healthcare Monthly Report from TM Capital. It covers the latest industry M&A deal activity and news, as well as trends in valuation. #TMCapital #ExtraordinaryOutcomes #ClientCare #Healthcare #BioTech #Pharma #LifeScience #Diagnostics #MedicalDevices #MergersandAcquisitions #InvestmentBank #FinancialAdvisor #Atlanta #NewYork #Boston